>> If it wasn't for the toxicity, Ariad would redefine the space, imo.
That's like saying nothing in drug development. If it weren't for toxicity, many more drugs with great efficacy would have been on the market.
Per EPIC ASCO poster disclosure:
Consider EPIC trial had very short follow-up, given the number above at termination and further follow-up, thus even if FDA hadn't taken action against Iclusig last year, EPIC trial could still be stopped due to safety issue by DMC before planned interim efficacy analysis originally planned for later this year if trial had continued.
By the way, I have to give ARIA credit for much thorough in data presentation from clinical trials since ASH last year than before. This is something every drug company especially small biotech should do but somehow don't. Without, it is very difficult to assess a drug's overall risk/benefit accurately.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.